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Parathyroid hormone-related protein (PTHrP) is an
integral mediator of physiologic and pathologic processes
and has demonstrated actions in the periodontium.
PTHrP functions via AP-1, and specifically through
JunB. This study identified JunB-dependent downstream
mediators of PTHrP using OCCM cementoblastic trans-
fectants with JunB over- or reduced expression. Over-
expressing cells showed an increase in proliferation, while
the opposite was seen in siRNA transfected cells. Micro-
array analysis of over-expressing cells revealed more than
1000 regulated genes. Three genes were investigated in
more detail. The PTH⁄PTHrP receptor (PTHR1) and
ephrin B1 (EfnB1) were down-regulated, and vascular
cell adhesion molecule-1 (VCAM-1) was up-regulated
with JunB over-expression. JunB siRNA transfectants had
increased PTHR1, but reduced ephrin B1 and unaltered
VCAM-1 in vitro. To validate these targets, parental
OCCM cells and primary osteoblasts were treated with
PTHrP, resulting in reduced PTHR1 and ephrin B1, and
increased VCAM-1. Cell transfectants were implanted
subcutaneously in vivo, and microarray analysis and
RT-PCR performed. Over-expression of JunB down-
regulated PTHR1 and ephrin B1, and increased VCAM-1.
JunB siRNA transfectant implants had increased PTHR1
and ephrin B1, but no altered VCAM-1. These data
highlight new gene targets for PTHrP and indicate JunB is
a critical mediator of PTHrP actions.
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Introduction
Parathyroid hormone-related protein (PTHrP) is an
autocrine, paracrine or intracrine factor during normal
development and pathologic conditions (Fiaschi-Taesch
and Stewart, 2003). PTHrP binds to the PTH ⁄PTHrP
receptor (PTHR1) on osteoblasts and cementoblasts to
invoke numerous downstream genes in a similar manner
as PTH, which binds to the same receptor (Gensure
et al, 2005). Signaling through the PTHR1 is primarily
through the PKA pathway, but the PKC and the
MAPK pathways also participate in PTH and PTHrP
actions in bone (Gensure et al, 2005).
Members of the AP-1 family of transcription factors
have prominent roles in skeletal development and
homeostasis (Eferl and Wagner, 2005). More than 45
genes important in bone have AP-1 sites in their
promoter region (Yamashita and McCauley, 2006),
and gene deletion and transgenic models of AP-1 factor
over-expression have revealed critical roles for Fos and
Jun family members in osteoblastic and osteoclastic cell
lineages (Jochum et al, 2001). PTH and PTHrP treat-
ment of osteoblasts results in a dramatic up-regulation
of AP-1 family members (Yamashita and McCauley,
2006), and previous studies from our laboratory have
characterized the AP-1 response in osteoblasts and
cementoblasts (Berry et al, 2006). Cementoblasts are
mesenchymal cells located on the tooth root surface
which have osteoblast phenotypic characteristics (Say-
gin et al, 2000). PTHrP binds to its receptor on
cementoblasts and up-regulates all of the Fos family
members, but only the JunB protein of the Jun family
(Berry et al, 2006). JunB has been found to function in
osteoblasts, osteoclasts, and cementoblasts (Kenner
et al, 2004; Berry et al, 2006); hence identifying the
downstream genes that PTH and PTHrP activate
through JunB would be a valuable aid in exploring the
effect of these important compounds on mineralized
tissues.
Parathyroid hormone and PTHrP support osteocl-
astogenesis via the up-regulation of RANKL and
down-regulation of osteoprotegerin (OPG) (Lee and
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Lorenzo, 1999), and PTHrP is critical for the support
of osteoclasts in the developing alveolar bone, as mice
with compromised PTHrP signaling lack tooth erup-
tion (Philbrick et al, 1998). Unlike osteoblasts,
cementoblasts do not normally support osteoclastogen-
esis, however PTHrP influences osteoclastogenesis by
cementoblasts at least in part through PTHrP’s action
via JunB. Cementoblasts produce high levels of osteo-
protegerin, and JunB activation via PTHrP results in a
diminution of OPG and a resulting increase in osteo-
clastogenesis (Boabaid et al, 2004). However, neither
the diminution of OPG nor an up-regulation of
RANKL can explain the entirety of PTHrP actions.
The purpose of the current study was to identify novel
downstream mediators of PTHrP action via its up-
regulation of JunB in a mesenchymal cementoblastic
cell line in vitro, and validate these findings in an
in vivo implant model.
Materials and methods
Cell culture and transfection
A subclone of the OsteoTag mouse-derived cemento-
blast cell line named OCCM.30 (OCCM) was cultured
as previously described (D’Errico et al, 2000). Briefly,
cells were maintained in DMEM (Invitrogen, Carlsbad,
CA, USA) supplemented with 10% fetal bovine serum
and 100 U ml)1 penicillin and 100 lg ml)1 streptomycin
(Invitrogen) at 37C in a humidified atmosphere of 5%
CO2. Primary calvarial cells were isolated as previously
described and cultured under the same conditions (Koh
et al, 1999).
Constructs were developed for over- and under-
expression of JunB as previously described (Berry et al,
2006). For over-expression of JunB, full-length junB was
cloned into pEF6⁄V5-His TOPO TA expression vector
(Invitrogen). The JunB over-expressing vector or a vector
alone control was transfected into OCCM cells using a
cationic lipid reagent (Lipofectamine 2000; Invitrogen)
and stable transfectants were established then subcloned.
Levels of JunB over-expression in transfectants were
measured using an AP-1 specific ELISA (Active Motif,
Carlsbad, CA, USA), and also byWestern hybridization.
Subclones were screened on the basis of expression level,
and subclones of each line (over-expressing and vector)
were selected for further study, hereafter referred to as
over-expressing JunB (OEJB.8) andvector control (OEV)
respectively. OEJB.8 exhibited an approximately 7-fold
increase in JunB expression as compared with the OCCM
parental clone and OEV. For reduced expression of
JunB, a custom pool of junB siRNA constructs were
made by Dharmacon Research (Lafayette, CO, USA),
which was employed in transient transfection experi-
ments using a cationic lipid reagent (Oligofectamine,
Invitrogen). The most effective sequence for silencing
from the pool was determined to be GGATCCCAA-
ATGCGCTCCTGGTCTTCCATTGATATCCGTGG-
AAGACCAGGAGCGCATTTTTTTTTCCAAAAG-
CTT. This was synthesized by GenScript (Piscataway,
NJ, USA) and cloned into siRNA expression vector
pRNAT-U6.1⁄Neo for stable transfection. The negative
control was a nonsense construct, pRNAU-6.1/Neo/
CTL, also from Genscript, containing sequence GGAT-
CCCGTCGCTTACCGATTCAGAATGGTTGATAT-
CCGCCATTCTGAATCGGT. The silencing constructs
and controls were transfected into OCCM cells using
Lipofectamine 2000 (Invitrogen), and stable transfec-
tants were established and subcloned. Levels of JunB
under-expression were measured as above, and sub-
clones of each line (under-expressing and nonsense
control) were selected for further study, hereafter
referred to as Si6.1 and control SiV. Si6.1 exhibited a
level of JunB expression approximately half that of the
vector control.
For PTHrP treatment experiments, cells were plated
at 2 · 104 cells cm)2 in 60-mm dishes in DMEM sup-
plemented as described above. On day 4 after plating,
medium was switched to DMEM with 5% FBS, and on
day 7 cells were treated with vehicle control or 100 nM
PTHrP (1–34) (Bachem, King of Prussia, PA, USA) for
various time periods, after which cells were harvested for
protein or RNA isolation.
Cell enumeration and apoptosis
To determine cell numbers over time, cells were plated at
a density of 1.04 · 103 cm)2 in 6-well plates. Beginning
on day 3 after plating, triplicate wells were trypsinized
and counted daily for 7 days using trypan blue exclusion
to determine viability.
To evaluate apoptosis, cell transfectants were plated
at approximately 2.4 · 104 cm)2 in 100 mM dishes and
2 days later harvested after a PBS wash, by scraping in
CelLytic MT mammalian tissue lysis extraction reagent
(Sigma-Aldrich, St Louis, MO, USA) with 1% Protease
Inhibitor Cocktail (Sigma). Lysates were incubated on
ice for 30 min with vortexing every 10 min, then
centrifuged at 22 000 g at 4C for 20 min. Supernatants
were stored at )80C until analyzed via Western
blotting. Cell viability as measured by trypan blue dye
exclusion was verified to be similar in parallel cultures of
the transfectants. Positive controls included OEV cells
treated with the pro-apoptotic agent staurosporine
(25 nM) (Sigma) for 6 h.
Western blot analysis was performed after running
30 lg of each sample on 10% acrylamide gels. Filters
were blocked for 1 h in 5% non-fat milk in Tris-buffered
saline with Tween-20 (TBST), probed overnight with
caspase 3 (Becton Dickinson, Franklin Lakes, NJ, USA)
and poly(ADP-ribose) polymerase-1 (PARP-1) (Cell
Signaling, Danvers, MA, USA) antibodies, then rinsed
with TBST and probed with appropriate secondary
antibodies (GE Healthcare, Piscataway NJ, USA). After
extensive rinsing with TBST, filters were incubated with
enhanced chemiluminescence reagents (Pierce Biotech-
nology, Rockford, IL, USA) and exposed to BioMax
film. Bands were normalized with actin, and compared
using either SCION IMAGE analysis program (Scion
Corporation, Frederick, MD, USA) or a Chemidoc
visualization⁄quantification system (Bio-Rad Laborato-
ries, Hercules, CA, USA). Relative band densities were
evaluated using INSTAT statistical analysis program
(GraphPad, San Diego, CA, USA).
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All animals were maintained in accordance with NIH
and institutional animal care guidelines, and experi-
mental protocols were approved by the Institutional
Animal Care and Use Committee of the University of
Michigan. Transfected cell lines were implanted sub-
cutaneously in a similar manner as previously described
for bone marrow stromal cells (Pettway et al, 2005).
Briefly, 1 · 106 cells were placed in a gelfoam carrier
sponge and implanted over the backs of athymic nude
mice (Harlan, Indianapolis, IN, USA) under anesthe-
sia. Four weeks later, mice were sacrificed and implants
were removed and either prepared for histology or
immediately frozen at )70C for further processing and
evaluation of RNA.
Protein isolation and analysis
For determination of JunB levels, nuclear extracts were
prepared and analyzed using both the TransAM AP-1
Family Transcription Factor Assay System (Active
Motif) and Western hybridization (Novex gels; Invitro-
gen). Briefly, cells were collected in cold PBS in the
presence of phosphatase inhibitors and resuspended in a
hypotonic buffer. Detergent was added to cause leakage
of cytoplasmic proteins into the supernatant, which was
removed. Nuclei were lysed and nuclear proteins were
solubilized in a lysis buffer containing protease inhibi-
tors. Samples were stored at )70C until the assays were
performed. Total protein levels were equalized as
measured using a Bradford-based assay (Bio-Rad),
and specific ELISA and Western hybridization were
performed to detect JunB. ELISAs were performed a
minimum of three times, and protein expression data
were analyzed using INSTAT statistical software (Graph-
Pad). Western blots were performed a minimum of three
times, and actin was measured in each sample as a
loading control (both antibodies Santa Cruz Biotech-
nology, Santa Cruz, CA, USA). Western films were
scanned, and relative protein expression was quantified
using either SCION IMAGE analysis program (Scion
Corporation) or a Chemidoc visualization⁄quantification
system (Bio-Rad). Relative band densities were evalu-
ated using INSTAT.
RNA isolation and analysis
RNA from both cells and implants was isolated using
Trizol (Invitrogen) and phase-lock gel (Eppendorf,
Westbury, NY, USA). In the case of cells, Trizol was
added directly to the plate, cells were scraped, and
solution was transferred to a tube containing phase-lock
gel for further processing. In the case of implants, the
tissue, flash frozen in liquid nitrogen immediately after
removal from the mouse, was crushed in liquid nitrogen,
mixed with Trizol, and this mix of tissue and Trizol was
then transferred to a tube containing phase-lock gel. In
both cases, samples were centrifuged, precipitated in
isopropanol, resuspended in DEPC-treated water, and
quantified spectrophotometrically. RNA samples to be
examined by microarray or real-time RT-PCR were
further purified, including treatment with DNAse using
an RNeasy kit (Qiagen, Valencia, CA, USA).
For Northern hybridization, 2–3 lg of RNA was
denatured, fractionated by electrophoresis on 1.2%
agarose 6% formaldehyde gel, transferred to a nylon
membrane (Duralon, Stratagene, La Jolla, CA, USA),
and cross-linked by UV radiation. Blots were hybridized
with random-primed [a32-P] labeled probes (Rediprime;
GE Healthcare) and were exposed to Kodak X-Omat or
Biomax film with intensifying screens at )70C for
4–24 h. Probes used included bone sialoprotein (BSP)
(Young et al, 1994), osteocalcin (OCN) (Celeste et al,
1986), and junB (McCabe et al, 1995). A cDNA for 18S
rRNA was used to probe and normalize blots. Northern
blot experiments were repeated a minimum of three
times using independent RNA samples, films were
scanned, and relative gene expression was quantified
using SCION IMAGE analysis program (Scion Corpora-
tion) after subtraction of background. Data were
analyzed using INSTAT statistical software (GraphPad).
For microarray analysis, total RNA samples were
evaluated spectrophotometrically to determine concen-
tration and purity, and RNA integrity was validated by
running on an agarose gel. Ten microgram of total RNA
was quantitatively amplified and biotin-labeled accord-
ing to the GeneChip Expression Analysis Technical
Manual (Affymetrix, Inc., Santa Clara, CA, USA).
Briefly, RNA was converted to double-stranded com-
plementary DNA (cDNA) using SuperScript II RT
(Invitrogen), with a T7-(dT)24 primer (Affymetrix). The
cDNA was then used in an in vitro transcription reaction
in the presence of biotin-modified ribonucleotides
(Enzo, Farmingdale, NY, USA) to produce large
amounts of single stranded RNA. Biotin-labeled RNA
was fragmented and 10 lg was hybridized to GeneChip
array Mouse Genome 430A’ (Affymetrix) at 45C for
16-h. Labeled bacterial RNAs of known concentration
were spiked in hybridization to generate an internal
standard and to allow normalization between chips.
Chips were washed and stained with streptavidin
R-phycoerythrin (Molecular Probes, Eugene, OR,
USA). After scanning the chips, the data were analyzed
by using Affymetrix GeneChip related software includ-
ing GCOS and Data Mining Tool. The microarray
experiments were performed three times (in vitro sam-
ples twice, in vivo samples once) and selected genes were
validated by real-time RT-PCR.
Real-time quantitative RT-PCR utilized the ABI 7500
system (Applied Biosystems, Foster City, CA, USA).
For reverse transcription (RT), a 25 ll RT reaction with
0.5 lg total RNA and random hexamers was performed
using TaqMan Reverse Transcription Reagents (Ap-
plied Biosystems). PCR was performed by using Taq-
Man Universal PCR Master Mix (Applied
Biosystems). Briefly, a 30 ll PCR reaction was prepared
with 1 ll cDNA (RT product) and 1.5 ll mixture of
TaqMan Gene Expression Assays probe and primers
mixture, specified as follows: PTHR1 ABI#
Mm00441046_m1 with probe sequence CTGCACA-
CAGCAGCCAACATAATGG, NBI Accession#
NM_011199.1; VCAM1 ABI# Mm00449197_m1 with
probe sequence GGAGGTCTACTCATTCCCTGAA-
GAT, NBI Accession no. NM_011693.2; EfnB1 ABI#
PTHrP and JunB
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Mm00438666_m1 with probe sequence CTGGAGCT-
CTCTTAACCCTAAGTTC, NBI Accession # NM_
010110.2. Thermal conditions were: 50C 2 min, 95C
10 min followed by 40 cycles of 95C 15 s and 60C
1 min. Expression levels of genes of interest were
normalized by comparison to TaqMan Rodent GAPDH
Control Assay of each sample. Real-time RT-PCR
was repeated a minimum of three times with similar
results.
Results
Over-expression of JunB increases, and silencing inhibits,
proliferation in cementoblasts
The OCCM cementoblastic cells were easily transfected,
and numerous subclones of JunB over-expressing and
siRNA lines were generated. Cell lines were screened at
the RNA and protein levels to validate the expected
altered gene expression (Figure 1). Several cell lines were
evaluated in the various assays, and selected clones are
shown. The OEJB.8 subclone of JunB over-expressing
cells displayed an approximately 7-fold increase in
mRNA for junB and an approximately 2-fold increase
in protein levels compared with OEV, the vector control.
The Si6.1 subclone of JunB siRNA cells displayed a
45% decrease in mRNA for junB and a 50% decrease in
protein levels compared with its vector control, SiV. As
AP-1 family members have been reported to alter cell
proliferation, an evaluation of cell numbers over time
was performed. Over-expression of JunB resulted in
increased cell numbers after 5 days (Figure 2a). In
contrast, knock down of JunB resulted in lower num-
bers of cells over time (Figure 2b). Western hybridiza-
tion analysis examining cleavage of PARP-1 and
caspase-3 were performed to characterize the difference
in cell numbers relative to apoptosis (Figure 2c). The
OEJB.8 transfectants showed a small but detectable
band of cleaved PARP, however there was no significant
cleavage of PARP-1 or caspase-3 in any of the cell
transfectants either over- or under-expressing JunB,
suggesting that apoptosis was not a prominent occur-
rence under the culture conditions. These data indicate
that the increase in cell numbers associated with JunB
over-expression is not because of reduced apoptosis, but
instead because of changes in proliferation.
Genes altered by JunB up-regulation in vitro, PTHR1,
VCAM-1 and EfnB1, identified by microarray and
validated by real-time RT-PCR
AP-1 sites are present in a wide variety of genes, many of
which are important in mineralized tissues (Yamashita
and McCauley, 2006). To elucidate genes that are
specific targets of JunB action, a microarray analysis
was performed on the OCCM transfectants that over-
expressed JunB as compared with control transfectants.
There were more than 600 genes identified as being up-
regulated 2-fold or more by JunB and more than 750
genes identified as being down-regulated 2-fold or more
by JunB (Table 1 and Supporting information). If genes
were detected more than once per chip, the fold change
is seen as an average of the values.
Several genes of interest were studied further, and
three were evaluated in detail and presented here. The
PTHR1 was selected because it was found to be highly
down-regulated by JunB over-expression in the micro-
array (28-fold) and because it is well known to be down-
regulated by PTH and PTHrP at the RNA level, but
very little information exists regarding the operative
transcriptional mediators. JunB over-expression nearly
abolished expression of the PTHR1 as measured by real-
time PCR and a 2.5-fold increase in the PTHR1 was
found in the junB siRNA transfectants as compared
with the control transfectants (Figure 3a). Vascular cell
adhesion molecule-1 (VCAM-1) was selected because it
was found to be up-regulated 3-fold in the microarray
data with over-expression of JunB, because it has not yet
been reported to be mediated by PTHrP, and because of
its reported role in osteoclastogenesis (Michigami et al,
2000). Validation by RT-PCR revealed an approxi-
mately 2.5-fold up-regulation of VCAM-1 by JunB
over-expression, however no regulation was found when
JunB was silenced (Figure 3b). Ephrin B1 (EfnB1) was
selected because it was down-regulated 5-fold by the
over-expression of JunB in OCCM cells in the micro-
array analysis, because it had not been previously
reported to be a PTHrP target and because of its novel
role in craniofacial development (Twigg et al, 2004).
Ephrin B1 was dramatically down-regulated by JunB
over-expression as confirmed by RT-PCR with levels at
10% of controls (Figure 3c). However, silencing JunB
did not result in an opposite effect, as siRNA for JunB
also resulted in down-regulation of Ephrin B1 in vitro as
measured by RT-PCR, although to a much lesser extent.
Silencing of JunB attenuates PTHrP effects in
cementoblasts
To determine if the reduction in JunB compromised
the PTHrP effects on these genes, OCCM parental cells
and JunB silenced (Si6.1) or vector control (SiV) cells
were treated with PTHrP or vehicle and RNA isolated
and analyzed by real-time PCR. The PTHR1 and
JunB
Actin





SiV       Si6.1    OEV    OEJB.8
Figure 1 JunB levels in transfectants. (a) Northern blot analysis of
junB mRNA levels from OCCM cell transfectants, (b) Western blot
analysis of JunB protein levels in nuclear extracts from OCCM cell
transfectants. The vector control cells for both the JunB silencing (SiV)
and over-expression (OEV) showed similar protein levels of JunB as
the parental OCCM cells. JunB silenced cells (Si6.1) had reduced JunB
mRNA and protein, while over-expressing cells (OEJB.8) had higher
JunB as compared with the respective vector controls
PTHrP and JunB
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ephrin B1 responses were attenuated (Figure 3d).
When JunB was silenced, PTHrP treatment did not
lower the PTHR1 or ephrin B1 levels to the same
extent as it did in controls, suggesting that JunB is key
for the gene effects. Interestingly, the VCAM levels
were similar and elevated with PTHrP regardless of
JunB silencing, suggesting JunB may not be the only
factor to contribute to the PTHrP mediated increase in
VCAM-1 (Figure 3e).
Increase in junB expression levels precede effects of
PTHrP on PTHR1, EfnB1 and VCAM-1 in cemento-
blasts and osteoblasts
To substantiate that JunB regulation resulted in
downstream gene alterations that were consistent with
a PTHrP effect, parental OCCM cells were treated
with PTHrP and gene expression for PTHR1, VCAM-
1 and Ephrin B1 was measured by RT-PCR over
time. There was significant down-regulation of
PTHR1 and ephrin B1 at 4 and 8 h (Figure 4a).
PTHR1 remained significantly down-regulated at 24 h,
while ephrin B1 recovered slightly (not shown).
VCAM-1 mRNA levels were significantly up-regulated
by PTHrP at 4 and 8 h (Figure 4a), and stayed
significantly elevated at 24 h. To compare the PTHrP
impact on cementoblasts with osteoblasts, similar
experiments that focused on the early time-points
where the greatest change was found were performed
with primary osteoblastic cells in vitro. Osteoblasts
displayed a similar trend with increased expression of
H
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Figure 2 Proliferation of JunB transfectants. OCCM transfectants were plated at 1 · 103 cells cm)2 and cell numbers determined over time. (a)
JunB over-expressing transfectants, (b) JunB siRNA transfectants. Over-expression of JunB caused an increase in cell numbers, while silenced cells
exhibited lower cell numbers over time as compared with vector controls. Data is expressed as mean ± s.e.m. of triplicate samples. ***P < 0.001
vs OEV control, **P < 0.01 vs OEV control, and *P < 0.05 vs SiV control, (c) Western blot for apoptotic markers in JunB transfectants. Each
lane loaded with 30 lg protein; positive control was OEV cells treated for 6 h with 25 nM staurosporine. There were no differences in cleaved
PARP-1 or caspase-3 in transfectants
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VCAM-1 and reduced expression of ephrin B1 and
PTHR1 (Figure 4c). Notably, in all studies osteoblasts
had higher baseline values of VCAM-1 than cemento-
blasts, and although they did display a PTHrP-
mediated increase in VCAM-1, they did not have as
dramatic an up-regulation in response to PTHrP.
Gene expression for junB in response to PTHrP
followed an earlier time course consistent with junB
preceding the downstream gene expression. Maximal
expression of junB in response to PTHrP in cemento-
blasts and osteoblasts was 1–2 h (Figure 4b,d).
Effects of JunB over-expression evaluated in vivo
In vitro model systems are powerful tools to identify
gene targets and begin to sort out mechanisms of protein
action, but at times do not always replicate the in vivo
state because of a plethora of other cells and factors that
can modify target gene expression. To validate the
in vitro findings in the context of a whole animal,
OCCM transfectants were implanted subcutaneously
into immunocompromised mice. Cementoblast implants
were examined histologically and mRNA was isolated
and gene expression analyzed by microarray and real-
time PCR. Control implants presented with a well-
defined proliferation of cells with round to elongated
basophilic nuclei (Figure 5a,c,e). A prominent accumu-
lation of eosinophilic calcified material consistent with
osteoid or cementum was found forming a fine mesh-
work of trabeculae lined by cells with hyperchromatic
angular nuclei. Cells were also contained within lacunar
spaces within the calcified material similar to osteocytes
or cementocytes. Numerous small vascular channels
were observed throughout the control specimens.
Implants with cells over-expressing JunB (Figure 5b,d)
presented as densely cellular with a brisk mitotic rate,
abundant pleomorphism, less vascularity than vector
implants and lacked visible mineralization. A pale-
staining, basophilic acellular material representing
residual gelfoam scaffold was found in the JunB over-
expressing implants but very little in other implants. The
implants with silencing transfectants appeared similar to
the vector controls. (Figure 5f).
The overall size of the implants upon gross exam-
ination revealed reductions in the size of implants
that contained either the JunB over-expressing or the
silenced transfectants (Figure 5g). To ascertain the
impact of JunB on parameters of differentiation
relative to cell mineralization, OCN gene expression
was determined in implants from transfectants. Silenc-
ing of JunB led to increased OCN whereas over-
expression of JunB led to a dramatic down-regulation
of OCN (Figure 5h).
Microarray analysis of gene expression influenced by
JunB in vivo examined and validated by real-time
RT-PCR
Microarray analysis of implants from mice with over-
expressing transfectants revealed more than 700 genes
up-regulated 2-fold or greater and more than 1250
genes down-regulated (Table 2 and Supporting infor-
mation). If genes were detected more than once per
chip, the fold change is seen as an average of the
values. Similar to the in vitro findings, the PTHR1
was nearly abolished by JunB over-expression,
whereas silencing resulted in an up-regulation of the
PTHR1 as determined by real-time PCR (Figure 6a).
Over-expression of JunB in implants resulted in a
dramatic 8-fold increase in VCAM-1 but no alteration
was found with silencing of JunB in vivo (Figure 6b).
Ephrin B1 was down-regulated 3-fold in vivo with
JunB over-expression and, unlike the results found
in vitro, up-regulated significantly with JunB silencing
(Figure 6c).
Comparison of genes regulated in vivo and in vitro
A comparison of genes regulated in vitro and in vivo was
performed as a means to better understand the JunB
gene targets (Table 3 and Supporting information). Of
note, genes associated with late stages of mineralization
such as BSP, OCN and dentin matrix protein-1 (DMP-
1) were down-regulated, and to a greater extent in vivo
Table 1 Microarray data of cell transfectants in vitro microarrays were
performed using RNA isolated from JunB over-expressing cells
(OEJB.8) or vector control (OEV)
GenBank no. Gene name
Fold
change
AV152334 ATPase, Na+K+ transporting,
beta 1 polypeptide
+16
AW494038 Calcium channel, voltage-dependent,
T type alpha 1G subunit
+10
NM_018857.1 Mesothelin +7
BB357126 Serinethreonine kinase 11 +7
NM_011361.1 Serumglucocorticoid regulated kinase +6
BC002081.1 Jun oncogene +4
NM_010107 Ephrin A1 +4
NM_011693.1 Vascular cell adhesion molecule 1 +3
NM_008597.1 Matrix gla protein +3
XM_892839 Ephrin A3 +3
NM_007910 Ephrin A4 +2
BI110565 Osteoblast specific factor 2 )246
NM_021355.1 Fibromodulin )50
BC013446.1 PTH receptor-1 )28
NM_008480.1 Laminin, alpha 1 )27
AW319615 Alkaline phosphatase 2 )20
NM_008318.1 Bone sialoprotein )16
BC019502.1 Biglycan )10
BB280300 Myocyte enhancer factor 2C )10




NM_009982.1 Cathepsin C )8
NM_010207.1 Fibroblast growth factor receptor 2 )7
NM_008393.1 Iroquois related homeobox 3 )7
BI111620 Tissue inhibitor of metalloproteinase 3 )7
NM_012050.1 Osteomodulin )6
NM_010110.1 Ephrin B1 )5
NM_007541.1 Osteocalcin )5
BB732264 Cadherin 2 )4
NM_130458.1 Osterix )4
U65020.1 Dentin matrix protein 1 )2
A selected list of genes altered by JunB over-expression is provided
here (see Supporting information for more extensive list). Genes
evaluated in detail are indicated in bold. For genes detected more than
once in the array, fold change is expressed as an average of all
readings.
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than in vitro. Furthermore, the inhibitor of mineraliza-
tion, matrix gla-protein was up-regulated. This suggests
that JunB is associated negatively with mineralization,
but could also reflect a later stage of cell differentiation
operative in the in vivo model.
Discussion
The present study identified new gene targets of PTHrP
that are downstream of JunB in cementoblast cells and
characterized these both in vitro and in vivo. PTH and
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Figure 3 Real-time PCR validation of three selected genes identified in microarray analysis from transfectants in vitro. (a) PTHR1 gene expression
in JunB over-expressing (OEJB.8) and vector control (OEV) cells (left), PTHR1 gene expression in JunB siRNA (Si6.1) and vector control (SiV)
cells (right), (b) VCAM-1 gene expression in OEJB.8 and OEV cells (left), VCAM-1 gene expression in Si6.1 and SiV cells (right), (c) Ephrin B1 gene
expression in OEJB.8 and OEV cells (left) Ephrin B1 gene expression in Si6.1 and SiV cells (right). (d) PTHR1 (left) and Ephrin B1 (right) or, (e)
VCAM-1 gene expression in response to PTHrP treatment (100 nm; 4 h) in parental OCCM, SiV or Si6.1 cells. (a–c) Data is expressed as
mean ± s.e.m. of triplicate samples and assays repeated at least four times with similar results. (d, e) Data is expressed as treatment over control
(T⁄C) of triplicate samples and mean ± s.e.m. with assays repeated at least two times with similar results. ***P < 0.001 vs respective vector
control, **P < 0.01 vs respective vector control, *P < 0.05 vs respective vector control
PTHrP and JunB
JE Berry et al
719
Oral Diseases
PTHrP are well known for their critical biological
activities during normal development and pathologic
conditions in bone, specifically on target osteoblastic
cells, and have also been found to be important in tooth
development and eruption. PTH and PTHrP often
display differing actions on downstream genes when
comparing effects in various model systems. For exam-
ple, PTH has been shown to have opposing effects on
transformed osteoblasts vs primary osteoblasts, where
PTH up-regulates BSP in osteosarcoma cells but down-
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Figure 4 Time course of PTHrP action on OCCM cell gene expression in vitro for PTHR1, VCAM-1, and Ephrin B1. (a) Parental OCCM cells
were treated for 0–8 h with 100 nM PTHrP and gene expression measured by realtime RT-PCR. PTHR1 levels were 2.4-fold lower at 4 hand 2.5-
fold lower at 8 h (P < 0.001 vs time zero). Ephrin B1 levels were 2.4-fold lower at 4 h and 1.9-fold lower at 8 h (P < 0.05 vs time zero). VCAM-1
levels were 2.9-fold higher at 4 h and 3.1-fold higher at 8 h (P < 0.05 vs time zero). (b) Parental OCCM cells were treated for 0–6 h with 100 nM
PTHrP and gene expression measured by northern blot analysis. junB levels were maximal at 1–2 h and decreased thereafter. (c) Primary murine
calvarial cells were isolated and cultured to confluence, followed by differentiation with 50 lM ascorbic acid for 7 days. Cells were then treated for
0–4 h with PTHrP (100 nM) and gene expression measured by real-time RT-PCR. PTHR1 levels were 1.4-fold lower at 2 h and 2.8-fold lower at
4 h (P < 0.001 for both) compared with time zero. Ephrin B1 levels were 1.3-fold lower at 2 h (P < 0.05) and 1.4-fold lower at 4 h (P < 0.01)
compared with control. VCAM-1 levels were 1.3-fold higher at 4 h (P < 0.01) compared with time zero. (d) Primary calvarial cells were treated for
0–6 h with 100 nM PTHrP and gene expression measured by northern blot analysis. junB levels were maximal at 1–2 h and decreased thereafter.
Data for a, c are plots from representative experiments repeated 2–3 times with similar results and expressed as mean ± s.e.m. of triplicate samples.
Data for b, d, are representative blots from experiments repeated a minimum of three times with similar results
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regulates it in primary calvarial cells (Yang and
Gerstenfeld, 1996; Ogata et al, 2000). Such apparently
contradictory findings have complicated the elucidation
of mechanisms of action of PTH and PTHrP in
mineralized tissues, but also suggest that the in vivo
effects of PTH and PTHrP may be indirect, and hence
other cellular targets may be operating in the down-
stream events.
Regarding a difference in pro- vs anti- proliferative
effects of PTHrP: in differentiated osteoblastic cells the
effect of PTH or PTHrP is to inhibit proliferation;
however, in sparsely seeded cultures in vitro or in an
in vivo implant model, PTH and PTHrP clearly lead to
pro-proliferative effects (Datta et al, 2005, 2007; Pettway
et al, 2008). In the present study, as the over-expressing







































Figure 5 JunB transfectants in vivo. Transfectants were implanted at 1 · 106 cells⁄implant in collagen sponges subcutaneously and monitored for
4 weeks prior to sacrifice and histologic processing. (a) OEV vector control implant, (b) OEJB.8 JunB over-expressing cell implant, (c) high power
view of OEV, (d) high power view of OEJB.8, (e) SiV, JunB silenced vector control, (f) Si6.1 JunB silenced cells. Photomicrographs of transfectants
revealed increased cellularity and polyploidy in JunB over-expressing cell (OEJB.8) implants, with less vascularity and no visible mineralization as
compared with vector control (OEV). Implants from JunB silenced cells (Si6.1) were similar in appearance to respective vector controls (SiV). Scale
A–F = 100 lm. (g) Implant size (n = 4–7⁄gp) Both over-expression and siRNA for JunB resulted in smaller implants than respective controls. (h)
Osteocalcin (OCN) expression in implants (n = 2–4⁄group). OCN was significantly increased in implants with siRNA knock down of JunB and
significantly decreased in implants with JunB over-expressing transfectants (P < 0.0001 for each compared with control)
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culture, they likely display the pro-proliferative JunB
effects that could be attributed to early PTHrP adminis-
tration. JunB under-expressing cells, on the other hand,
showa lower rate of proliferation,which is consistentwith
the lower proliferation rate seen in osteoblasts obtained
from mice lacking JunB (Kenner et al, 2004). In neither
case was apoptosis, as measured by PARP-1 and caspase-
3 cleavage, an evident factor in influencing cell number.
However, an exhaustive analysis of the proliferative and
apoptotic aspects ofPTHrPonmesenchymal cellswas not
performed in this study, as it was the focus of previous
reports, asmentioned above, and as the goal for this study
was to concentrate on downstream gene events.
One of the goals of the current study was to reveal new
gene targets that are operative both in vitro and in vivo as
a means to better identify the cellular targets and
mechanisms of PTH and PTHrP actions in mineralized
tissues. Three gene targets were identified and charac-
terized in further detail. The PTHR1 has previously been
identified as a down-regulated gene target of PTH and
PTHrP action in bone and cementum and served in
part to validate the model system. Ephrin B1 was also
down-regulated and was intriguing for its known role in
Table 2 Microarray analysis of cell transfectants in vivo












NM_020265.1 Dickkopf 2 +12
M12233.1 Actin, alpha 1,
skeletal muscle
+9








AV152334 ATPase, Na+K+ transporting,
beta 1 polypeptide
+3
NM_008597.1 Matrix gla protein +3
XM_892839 Ephrin A3 +2
NM_007910 Ephrin A4 +2
BB795191 Melanoma antigen )139
NM_008318.1 Bone sialoprotein )67
U65020.1 Dentin matrix protein-1 )35
NM_007541.1 Osteocalcin )21
BC022107.1 Cadherin 2 )9
AV291165 Myocyte enhancer factor 2c )9
NM_010056.1 Distal-less homeobox 5 )7
NM_008393.1 Iroquois related homeobox 3 )7
NM_130458.1 Osterix )7
BC013446.1 PTH receptor-1 )7
AW319615 Alkaline phosphatase 2 )6
NM_008592.1 Forkhead box C1 )5
NM_011607.1 Tenascin )5
NM_010110.1 Ephrin B1 )3
Microarrays were performed using RNA isolated from cementicle
implants in athymic mice. Implants were generated using JunB over-
expressing cells (OEJB.8) or vector control (OEV). A select list of genes
altered by JunB over-expression is provided here (see Supporting
information for more extensive list). Genes evaluated in detail are
indicated in bold. For genes detected more than once in the array, fold
change is expressed as an average of all readings.
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Figure 6 Real-time PCR validation of three genes identified in
microarray analysis from transfectants in vivo. Implants of OCCM
transfectants with JunB over-expressing (OEJB.8) and silenced (Si6.1)
cells and their appropriate controls (OEV and SiV) were harvested
after 4 weeks in nude mice. RNA was isolated, and real-time RT-PCR
was performed to analyze expression of the (a) PTHR1, (b) VCAM-1
and (c) Ephrin B1. Results are expressed as treatment⁄control (T⁄C),
and assays were performed on at least four implants each. Comparison
is shown on each graph between over-expressing and silenced implants.
(a) PTHR1 ***P < 0.001 compared with respective controls. (b)
VCAM-1 ***P < 0.001 compared with respective control. (c) Ephrin
B1 ***P < 0.001 and **P < 0.01 compared with respective controls
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craniofacial development. VCAM-1 was found to be
up-regulated, and this study is the first to identify it as a
gene target in response to PTH or PTHrP.
The PTHR1 is a seven transmembrane domain
receptor that is well characterized as being present in
the PTH target organs of bone and kidney. The PTHR1
is the product of a complex gene extending over 22 kb
and consisting of 15 exons and is well conserved across
species (Kong et al, 1994). Very little has been reported
of its transcriptional controls and promoter elements.
PTH and PTHrP have been reported to down-regulate
the PTHR1 at the mRNA level but AP-1 regulation of
the PTHR1 promoter has not been described. The
significance of PTH and PTHrP down-regulating their
own receptor is obvious, as it forms an easily regulatable
feedback system to prevent over-stimulation of the
PTHR1. Constitutive activation of the PTHR1 results in
the condition of Jansen’s chondrodysplasia (Schipani
et al, 1995). A notable mouse model of constitutive
activation of the PTHR1 demonstrates an anabolic
phenotype in trabecular bone (Calvi et al, 2001). That
PTHrP and JunB down-regulate the PTHR1 suggest
that they may be working to prevent and⁄or balance the
PTHR1 mediation of high bone mass and⁄or restrict or
limit the progress of tooth eruption that is dependent on
PTHrP expression.
Ephrin B1 is a member of a family of ligands for
ephrin receptors (Eph) (Davy and Soriano, 2005). The
Eph family is the largest family of protein tyrosine
kinase receptors and consists of six ephrin B receptors
(EphB) and 10 ephrin A receptors (EphA) (Zhao et al,
2006). The cell surface ephrin Bs (ephrins B1–B3) are
ligands for the EphBs and the ephrin As (ephrin A1–A5)
are ligands for the EphAs. Recently there is an evidence
that ephrins play critical roles in bone, and specifically in
the signaling between osteoblasts and osteoclasts (Zhao
et al, 2006). Interestingly, mutations in ephrin B1 in
humans have been found to be responsible for a
craniofacial abnormality called craniofrontalnasal syn-
drome (Twigg et al, 2004). Humans with this gene
mutation typically have hypertelorism, a nasal groove,
craniosynostosis and often present with cleft lip and
palate (Wieacker and Wieland, 2005). Mice with tar-
geted deletion of ephrin B1 are perinatal lethal (Davy
et al, 2004). Such findings have validated a role for
ephrin B1 in neural crest cell migration and in epithelial
mesenchymal boundaries. Ephrins are implicated in
maintaining cranial sutures, as a lack thereof has been
found to result in craniosynostosis (Merrill et al, 2006).
Expression of ephrin B1 in cementum could provide
signals necessary to maintain a periodontal ligament
space and prevent ankylosis. Data in the present study
indicate that PTHrP, via its up-regulation of JunB,
results in a reduction in ephrin B1 gene expression.
Interestingly, ephrin B1 has been shown to interact with
PSD-95/Dlg/ZO-1 (PDZ) binding intracellular proteins
and modify G-protein-coupled receptor signaling (Lu
et al, 2001). PDZ binding proteins have been found to
be important in regulating signaling of the PTHR1
(Mahon et al, 2002; Sneddon et al, 2003). It is possible
that the PTH down-regulation of ephrin B1 could be a
means to auto regulate signaling of the PTHR1.
Vascular cell adhesion molecule-1 is an adhesion
molecule that has been widely studied for its role in
vascular formation. VCAM-1 interacts with its receptor
a4b1 (VLA-4) (Lobb and Hemler, 1994). VCAM-1 was
first characterized for its expression on endothelial cells
and its ability to promote localization of circulating
lymphocytes to sites of vascular remodeling (Jin et al,
2006). Most immune cells including T- and B-lympho-
cytes and monocytes will bind to VCAM-1, and its
receptor VLA-4 is important for hematopoietic stem cell
renewal (Priestley et al, 2006). VCAM-1 has also been
implicated in its ability to support osteoclastogenesis by
stromal cells and in myeloma cell cultures (Feuerbach
and Feyen, 1997; Michigami et al, 2000). Inflammatory
cytokines such as interleukin-1 and tumor necrosis
factors have been shown to up-regulate VCAM-1, and
levels typically stay high for 48 h (Kindle et al, 2006). In
the present study, it was found that PTHrP via its up-
regulation of JunB resulted in an increase in VCAM-1
gene expression. These data suggest that PTHrP via JunB
may support bone resorption and⁄or hematopoietic cell
homing at least in part via the up-regulation of VCAM-1,
and this interaction could be a key in facilitating
resorption to allow for tooth eruption as well as a factor
in pathologic resorption in the case of disease.
The siRNA inhibition of JunB effectively reduced the
PTHrP impact on ephrin B1 and the PTHR1, as neither

















Matrix gla protein +3 +3
Ephrin A3 +3 +2
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Bone sialoprotein )16 )67
PTH receptor )28 )7
Alkaline phosphatase 2 )20 )6
Myocyte enhancer factor 2C )11 )10
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Comparison was performed between the microarrays from JunB
over-expressing cementoblast transfectants in vitro and their implants
in vivo. A selected list of genes altered by JunB over-expression in both
instances appears here (see Supporting information for complete list).
Genes investigated in detail are indicated in bold. For genes detected
more than once in the array, fold change is expressed as an average of
all readings.
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were down-regulated as much as vector controls. How-
ever, the PTHrP mediated impact on VCAM-1 was
unchanged in the JunB siRNA transfectants, with up-
regulation by PTHrP remaining strong. It is possible
that in the instance of VCAM-1 having two AP-1 sites in
its promoter (Niesh et al, 1992) that another AP-1
family member may be compensating for the reduction
in JunB. In fact, we previously reported that silencing of
JunB resulted in increased levels of phosphorylated
c-Jun (Berry et al, 2006). C-Jun often can have similar
functions as JunB in target promoters, and in fact has
been found to up-regulate VCAM-1 in other cell systems
(Ahmad et al, 1998). Hence, it is possible that the
decrease of JunB resulted in an up-regulation of c-Jun
activity that, in the case of VCAM-1, compensated for
the lack of JunB. This does not diminish that JunB
could mediate PTHrP effects at the VCAM-1 promoter,
but suggests that it is not the sole mediator of PTHrP
effects on this gene. Future studies that dysregulate both
JunB and c-Jun would be necessary to validate this. The
VCAM-1 promoter has 2 AP-1 sites, and the PTHR1
and the ephrinB1 promoter both have truncated AP-1
sites (Korenaga et al, 1997; Manen et al, 1998; Brown,
2007). Such truncated sites have been found to be
functional, but as with all AP-1 sites the effects are cell
context dependent (Chinenov and Kerppola, 2001;
Zhou et al, 2005).
The design of this study enabled interesting compar-
isons between in vitro and in vivo model systems and
between the over-expression and knock down of JunB.
The three genes selected are regulated both by JunB and
PTH⁄PTHrP, and include a known gene regulated by
PTH and PTHrP and two novel genes, one of which was
up-regulated and one down-regulated by JunB. The
pattern of responses was different for all three genes.
Regulation of the PTHR1 by JunB was strong and
consistent both in vitro and in vivo: over-expression of
JunB down-regulated the receptor in vitro and in vivo
and silencing JunB increased the receptor expression in
both cases. PTH and PTHrP down-regulation of their
receptor at the mRNA level has been reported (Koh
et al, 1999; Gensure et al, 2005), but the JunB mediation
of this had not previously been investigated. Although
c-Jun can replace the action of JunB in many circum-
stances, the data in the present study suggest that JunB
is essential for expression of the PTHR1. VCAM-1
expression was up-regulated by the over-expression of
JunB both in vitro and in vivo but silencing of JunB had
no effect on VCAM-1 in either situation. This suggests
that JunB is permissive for VCAM-1 expression but not
essential, and that other Jun family members may
substitute for the lack of JunB and⁄or that even low
levels of JunB are sufficient to drive baseline values of
VCAM-1. Ephrin B1 levels were down-regulated with
over-expression of JunB both in vitro and in vivo, but
silencing of JunB resulted in disparate results. In vivo
JunB silencing resulted in an expected opposite response
to over-expression with increased ephrin B1 expression.
However, in vitro, cells with JunB siRNA displayed
lower ephrin B1 levels. This suggests that although JunB
has a direct effect in cementoblasts to decrease ephrin B1
levels, the effects of reducing JunB levels are modified in
different ways by the surrounding environment. It is
possible that RNA isolated from the implant reflects
other cell types than just the cementoblasts, and
highlights the importance of in vivo studies to identify
operative indirect actions of PTH ⁄PTHrP.
Our results are summarized in Figure 7: PTH/PTHrP
works through its receptor, PTHR1, resulting in an
increase in JunB. Feedback to the receptor causes down-
regulation, while the increase in JunB initiates down-
stream effects including an increase in proliferation, an
increase in VCAM-1 (which is known to promote
osteoclastic activity), and alterations in genes involved
in mineralization including ephrin B1, OCN, BSP,
alkaline phosphatase, dentin matrix protein, and matrix
gla protein, all of which can lead to perturbations in the
normal mineralization process. These findings raise new
possibilities for the impact of PTHrP on cells in the
craniofacial apparatus in the support of osteoclastogen-
esis and epithelial mesenchymal interactions.
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